Skip to content

Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients

Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150622022869N11
Enrollment
70
Registered
2023-06-11
Start date
2023-06-20
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

helicobacter pylori (h. pylori) infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: First intervention group: omeprazole 20 mg twice a day (Bid) is continued for two weeks with antibiotics and then for 6 weeks without antibiotics, and after 4 weeks of this treatment p

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: A patient who underwent endoscopy and has peptic ulcer disease (PUD). Patients with dyspepsia without endoscopic indication have a positive Helicobacter diagnostic test, including Helicobacter stool antigen test and.... Patients with maltoma Endoscopy patients with nud (non-ulcer dyspepsia) and patients with a history of cancer in their first degree relatives will be included in the study. Patients who have a history of pud and are Helicobacter positive and are taking NSAID Treatment-resistant dyspepsia Patient satisfaction

Exclusion criteria

Exclusion criteria: Previous history of H pylori treatment Allergy to antibiotics Allergy to PPI History of gastrectomy Having gastric cancer pregnant women Taking antibiotics in the last month Taking PPI or h2blocker in the last two weeks Chronic liver, kidney or lung disease History of Fauvism

Design outcomes

Primary

MeasureTime frame
Frequency distribution of Helicobacter pylori antigen negativity. Timepoint: 12weeks after the start of the study. Method of measurement: Stool antigen test.;Drug side effects. Timepoint: 12 weeks. Method of measurement: Clinical examination and patient presentation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMoslem Sedaghttalab

Yasouj University of Medical Sciences

m.sedaghattalab@yuma.ac.com+98 74 3334 5876

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026